FDA approves NETSPOT for neuroendocrine tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved NETSPOT (Somakit-TATE) for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients. NETSPOT received approval following a Priority Review, and is currently approved for use with the GalliaPharm Ga 68 generator from Eckert & Ziegler. NETSPOT is the first approved drug using Ga 68 as a positron emitter. Gallium...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login